The stock price of Acorda Therapeutics Inc (NASDAQ: ACOR) has dropped by -19.64 compared to previous close of 1.68. Despite this, the company has seen a fall of -89.78% in its stock price over the last five trading days. Market Watch reported 2024-04-01 that Shares of Acorda Therapeutics ACOR, +1.96% fell late Monday after the company said it had filed for bankruptcy protection.
Is It Worth Investing in Acorda Therapeutics Inc (NASDAQ: ACOR) Right Now?
Additionally, the 36-month beta value for ACOR is 1.61. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 0 rating it as “overweight,” 7 rating it as “hold,” and 2 rating it as “sell.”
The public float for ACOR is 1.23M and currently, short sellers hold a 0.77% ratio of that float. The average trading volume of ACOR on April 08, 2024 was 89.10K shares.
ACOR’s Market Performance
The stock of Acorda Therapeutics Inc (ACOR) has seen a -89.78% decrease in the past week, with a -89.85% drop in the past month, and a -90.97% fall in the past quarter. The volatility ratio for the week is 44.54%, and the volatility levels for the past 30 days are at 15.14% for ACOR. The simple moving average for the past 20 days is -87.81% for ACOR’s stock, with a -89.92% simple moving average for the past 200 days.
Analysts’ Opinion of ACOR
Many brokerage firms have already submitted their reports for ACOR stocks, with H.C. Wainwright repeating the rating for ACOR by listing it as a “Buy.” The predicted price for ACOR in the upcoming period, according to H.C. Wainwright is $10 based on the research report published on June 17, 2021 of the previous year 2021.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ACOR reach a price target of $6, previously predicting the price at $31. The rating they have provided for ACOR stocks is “Neutral” according to the report published on August 14th, 2019.
ACOR Trading at -89.92% from the 50-Day Moving Average
After a stumble in the market that brought ACOR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -94.42% of loss for the given period.
Volatility was left at 15.14%, however, over the last 30 days, the volatility rate increased by 44.54%, as shares sank -90.12% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -91.95% lower at present.
During the last 5 trading sessions, ACOR fell by -89.78%, which changed the moving average for the period of 200-days by -88.84% in comparison to the 20-day moving average, which settled at $10.4583. In addition, Acorda Therapeutics Inc saw -91.05% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ACOR
Current profitability levels for the company are sitting at:
- -0.15 for the present operating margin
- 0.8 for the gross margin
The net margin for Acorda Therapeutics Inc stands at -2.15. The total capital return value is set at 0.16. Equity return is now at value -23.68, with -90.89 for asset returns.
Based on Acorda Therapeutics Inc (ACOR), the company’s capital structure generated 5.8 points at debt to capital in total, while cash flow to debt ratio is standing at -0.07. The debt to equity ratio resting at -1.21. The interest coverage ratio of the stock is -0.53.
Currently, EBITDA for the company is 8.4 million with net debt to EBITDA at 18.79. When we switch over and look at the enterprise to sales, we see a ratio of 1.38. The receivables turnover for the company is 6.8for trailing twelve months and the total asset turnover is 1.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.33.
Conclusion
In conclusion, Acorda Therapeutics Inc (ACOR) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
